

RANDOX

PROSTATE CANCER RISK BIOCHIP

EARLY DIAGNOSIS CAN MAKE A DIFFERENCE

Powered by Biochip Array Technology

Utilises a biomarker algorithm and clinical data to triage patients into 'low' to 'high' risk categories for potential risk of prostate cancer.



Biochip allows for **improved patient management** by identifying patients at risk of prostate cancer.



Biochip enables clinicians to **intervene early** and provide treatment at the onset of prostate cancer.



Biochip prostate cancer risk score is **independent of BMI**; a high BMI can lower PSA levels.




Biochip **reduces unnecessary referrals** to secondary care for invasive and costly biopsy investigations.

Data-Driven Risk Stratification

Recent studies by Randox have demonstrated that a novel serum combination of four biomarkers significantly improved the predictive potential of tPSA alone to identify patients with prostate cancer.

A patient triage pathway using Randox Biochip Array Technology allows patients at highest risk to be referred for urgent investigation while reducing the need for biopsy for those at low risk.



Over **50,000** men in the UK are diagnosed with prostate cancer each year.

Almost **75%** of patients referred for investigation have a negative prostate biopsy (150,000 patients).

Prostate cancer costs for the NHS exceeded **£320.6 million** in 2020.

Biomarkers

EGF	IL-8	MCP-1	tPSA
-----	------	-------	------

Product Information

 Sample Type Serum	 Samples Per Cartridge 2	 Sample Volume 250µl	 Result Type Quantitative	 Time to Result 60 Minutes
--	--	--	--	--

Prostate Cancer Risk Biochip – For use on the Evidence MultiSTAT analyser

marketing@randox.com | randox.com